🇺🇸 Methotrexate/Hydrocortisone in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 11
Most-reported reactions
- Hypertension — 2 reports (18.18%)
- Abdominal Compartment Syndrome — 1 report (9.09%)
- Drug Tolerance Decreased — 1 report (9.09%)
- Febrile Neutropenia — 1 report (9.09%)
- Fungal Infection — 1 report (9.09%)
- Hepatic Failure — 1 report (9.09%)
- Mental Status Changes — 1 report (9.09%)
- Pancytopenia — 1 report (9.09%)
- Renal Failure — 1 report (9.09%)
- Sepsis — 1 report (9.09%)
Other Oncology, Immunology approved in United States
Frequently asked questions
Is Methotrexate/Hydrocortisone approved in United States?
Methotrexate/Hydrocortisone does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Methotrexate/Hydrocortisone in United States?
Dana-Farber Cancer Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.